Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to $589000.0.

  • NovaBay Pharmaceuticals' Non-Current Assets fell 6314.14% to $589000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year decrease of 4639.97%. This contributed to the annual value of $1.5 million for FY2024, which is 2085.11% down from last year.
  • As of Q3 2025, NovaBay Pharmaceuticals' Non-Current Assets stood at $589000.0, which was down 6314.14% from $796000.0 recorded in Q2 2025.
  • NovaBay Pharmaceuticals' Non-Current Assets' 5-year high stood at $12.3 million during Q1 2022, with a 5-year trough of $589000.0 in Q3 2025.
  • Moreover, its 5-year median value for Non-Current Assets was $1.8 million (2024), whereas its average is $4.2 million.
  • As far as peak fluctuations go, NovaBay Pharmaceuticals' Non-Current Assets surged by 148531.0% in 2022, and later plummeted by 6554.55% in 2024.
  • Quarter analysis of 5 years shows NovaBay Pharmaceuticals' Non-Current Assets stood at $10.8 million in 2021, then tumbled by 53.12% to $5.1 million in 2022, then plummeted by 62.9% to $1.9 million in 2023, then decreased by 20.85% to $1.5 million in 2024, then plummeted by 60.42% to $589000.0 in 2025.
  • Its Non-Current Assets stands at $589000.0 for Q3 2025, versus $796000.0 for Q2 2025 and $834000.0 for Q1 2025.